Emergency anticoagulant reversal B Vigué, DAR, CHU Bicêtre.

Slides:



Advertisements
Similar presentations
Evidence-Based Management of Anticoagulant Therapy
Advertisements

Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
The Changing Landscape of Anticoagulation William D. Cahoon, Jr., PharmD, BCPS Cardiology Clinical Pharmacist VCU Health System April 12, 2012.
What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
Edward P. Sloan, MD, MPH Optimizing the Management of Emergency Department Intracerebral Hemorrhage Patients FERNE Satellite 2005 ACEP Scientific Assembly.
Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria
New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Dr Dipti.
ABC Advanced Bleeding Care Case: Spontaneous Kidney Rupture Santiago Ramón Leal-Noval.
CLINICAL CASES.
NEW ORAL ANTICOAGULANTS
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Dalia Elfawy., MD Lecturer of Anesthesia and ICU Ain Shams University 2014 RAPID REVERSAL OF ANTICOAGULATION IN TRAUMA PATIENTS.
Stroke Alert at Lutheran General Hospital, Park Ridge, IL
ANTICOAGULANT BY :DR ISRAA OMAR.
WARFARIN AN OVERVIEW.
Background Methods Results Conclusion Acknowledgements Printed by Multi-Institutional Audit of octaplex® & Comparison with National Recommendations S.
Care of the Anti-coagulated Trauma Patient Julie Mayglothling, MD, FACEP Emergencies in Medicine March 8 th, 2012.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Stroke and the ED Kurian Thomas, MD Department of Neurology.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
FERNE/EMRA How do we treat ICH patients with an elevated INR Andy Jagoda, MD, FACEP Professor and Vice Chair Department of Emergency Medicine Mount Sinai.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
Role of Factor Concentrates in Perioperative Coagulopathies Dr Neville Gibbs Department of Anaesthesia Sir Charles Gairdner Hospital.
1 Ultra-rapid management of oral anticoagulant therapy- related surgical intracranial hemorrhage Intensive Care Medicine (2007) 33: Zohra Daw, MD,
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Anticoagulants and reversal
General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental.
Factor Eight Inhibitor Bypassing Activity (FEIBA) for the Rapid Reversal of Major Bleeding in Patients with Warfarin Induced Coagulopathy: A Pilot Study.
Fred V. Plapp MD PhD Pathology and Laboratory Medicine
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
Stroke Protocol Time Lost Is Brain Lost!. Objective: Improve patient care & outcomes Offer a standard of care Increase efficiency Meet accreditation recommendations.
R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.
April 23, 2015 Mini-Lecture Nathan King M.D. Anticoagulation Reversal Part 1: Warfarin.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Evidence-Based Management of Anticoagulant Therapy
Prothrombin complex concentrate
Volume 149, Issue 6, Pages (June 2016)
AUB:Iatrogent Coagulopathy
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Paediatric Cardiac Pharmacist Bristol Royal Hospital for Children
Warfarin Toxicity Treatment & Management
Evaluation of Four Factor Prothrombin Complex Concentrate
Anticoagulation in Atrial Fibrillation
Tenecteplase (TNK-t-PA)‏
In the name of God. Management trauma in elderly DR. NIKSOLAT GERIATRICIAN ASSISTANT PROFESSOR, IRAN UNIVERSITY OF MEDICAL SCIENCE.
Anticoagulation Prepared by Cherie Gan.
Prothrombin Complex Concentrate(PCC)
Oral Anticoagulants and Reversal Agents
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Dabigatran in myocardial injury after noncardiac surgery
Reversal Strategies for VKA: Truths and Misconceptions
Neurosurgery and DOACs
Oral Anticoagulant Reversal Agents
Anticoagulant Reversal
Efficacy and safety outcomes with NOAC compared with warfarin in NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747.
Journal club govaresh Dr ali gavidel Dr sadr azar.
RE-ALIGN Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement.
Presentation transcript:

Emergency anticoagulant reversal B Vigué, DAR, CHU Bicêtre

1 to 2% of the population are prescribed VKA (Vitamin K Antagonist) - Annual incidence of hemorrhage is 4 to 13% [Hylek, Circulation, 2003] In France admissions per year in Emergency Department (ED) for bleeding under VKA (Sié 2002). In 2 month in a french universitary ED: 198 major bleedings, 34 for intracranial bleedings INR>5 : 150 to 450 cas in french county EDs Risk for intracranial haemorrhage: 1% per year

VKA decreases thrombotic risk - Cardiac Valves : Stroke : 4% / patient - year Aspirine : 2,2% / patient - year VKA : 1% / patient - year - Auricular Fibrillation Stroke around 4% / patient - year - Phlebitis and pulmonary embolism

Risk of VKA therapy VKA increases the risk for intracranial bleeding 7 to 10 fold Incidence : 0.3 to 1% per year Mortality: 60% VKA + intracranial haemorrhage expansion = 50% No VKA + intracranial haemorrhage expansion = 10% Risk factors for bleeding under VKA INR in over therapeutic zone (>4-5) HTA Starting treatment (first 3 month)

As soon as possible!!

FFP : fresh frozen plasma Risk of TRALI PCC (Prothrombin Complex Factor) : 4 factors superior to FFP No delay to normalize 60 ml of PCC = 2000 ml of FFP But factor VII 1/2 life = 5-6 hours Vitamin K : Delayed correction = 6 to 8 hours to be effective Which dose? Delayed correction No randomized trial

Thromb Haemost, 1997, United Kingdom 41 patients Retrospective study PCC : U IX / kg vs FFP (800ml) Vitamine K in all cases (1-5 mg IV) In 15 min : complete reversal for 28/29 patient with PCC and for 0/12 patients for PFC

60 ml PCC = 2000 ml of FFP

PCC superior to FFP for emergency reversal of VKA Needing of effective availability in all hospitals Administration «as soon as diagnostic confirmed»

Guidelines PCC(20-30 UI/kg) + Vitamin K (5-10 mg)

In France : management of INR in over therapeutic zone in cas of bleeding (n=198) Intravenous vitamine K alone = 44% Oral vitamine K alone = 5% Intravenous vitamin K = 41% PCC in association = 29% PCC alone = 7% FFP = 25% Under dosing of PCC (15 UI/kg instead of 20-30) Discrepancy between guidelines and reality (fear of thrombotic events, availability of product) Sié, 2002

PCCs are the most accurate solution to reverse anticoagulation Fact and hypothesis Intracranial bleeding under VKA : 50% mortality during the first month Stroke, 2001 Thromb Haemost, 1997 Delayed management could impair the prognosis “You wouldn't say that if you had seen a valve thrombosis”

To evaluate the rapidity of correction of INR after administration of PCC during the managment of neurosurgical bleeding Aim of the study

Methods Rapid intravenous administration (1 min) of two 2 doses of PCC (10 U/kg) Begining of surgical procedure immediately after Preparation of the operative room, installation of patient for craniotomy before any laboratory results or administration of PCC Laboratory study: PT and INR before infusions, between infusions, immediately after and 6 hours later Administration of oral vitamin K, 5 mg Inclusion criteria : patients under VKA admitted for intracranial bleeding requiring a neurosurgical procedure

Methods Emergency situation Be aware of pressure Come back to real risk Come back to the basics Create an emergency situation, a golden hour All are involved; emergency physicians, surgeons, anaesthesists, nurses Preparation of the operative room, installation of patient for craniotomy before any laboratory results or administration of PCC

Rapid intravenous administration (1 min) of two 2 doses of PCC (10 U/kg) Methods Dose of PCC: INR between 2 and 3,5 : administration of 10 to 20 UI/kg of factor IX to limit the thrombotic risk In INR in over therapeutic zone, 20 to 30 UI/kg of factro IX (25 UI/kg =1 ml /kg of factor IX) Administration: Rate of infusion slower than 4 ml/min : 68/4 = 17 mins !! Do not wait for laboratory control of reversal!

Laboratory study: PT and INR before infusions, between infusions, immediately after and 6 hours later Methods Do not wait for laboratory control of reversal! A race against time A place for bedside monitoring?

Methods Administration of oral vitamin K, 5 mg Oral vitamin K, efficiency to reverse anticoagulation in 6 to 12 hous (Br J of Haematology, 2001) Oral vitamin K, superior to sub-cutaneous vitamin K to reverse anticoagulation (Ann Intern Med, 2001) Oral vitamin K, equivalent to intravenous vitamin K to reverse anticooagulation (Ann Intern Med, 2003)

Results 18 patients included 12 subdural haematoma, 6 intracerbral haematoma No thrombotic complication Outcome : 13 patients with GOS 1 to 1, 4 patients died (23%)

SexeAge Reason for VKAGCSVolumeDose/kgGOS 1 F80FA146020,01 2 M73FA98022,52 3 M81FA96020,01 4 F71PHV66021,45 5 F71VTE66021,41 6 M62atherom108020,01 7 M82atherom67022,51 8 F54FA76025,02 9 M58PHV38020,05 10 F86AVC66030,02 11 F70FA86021,45 12 M56FA F73FA M58PHV F70FA M62VTE M78PHV F86VTE560225

admission1 min2 min6-12 h PT (%)20±962±1478±1566±17 PT (sec)40±2214±212±213±2 TCK (sec)53±1541±1040±1137±5 TT (sec)20±520±421±518±4 V (%)111±25107±25109±23111±25 II (%)33±2370±2094±2187±22 VII+X (%)15±1057±1578±1765±30 Results INR3,95±1,611,39±0,271,18±0,151,34±0,27

Results * * *

Progressive reinitiating of anticoagulation, No thrombotic event

Discussion 23% patients died (30 to 60 % in our litterature analysis) The gain of time improves the management of the urgent neurosurgery. No laboratory control are needed to begin the surgical procedure Think for vitamin K !!

Discussion Why PCC is not currrently used ?…

Conclusion (1/3) Ultra rapid reversal of anticoagulation without thrombotic events VKA reversal improves time to surgical procedure Outcome? Mortality?

Conclusion (2/3) There is no way to delay surgery Life-threatening events All urgent surgery (as peritonitis…) there is no way to delay the reversal of VKA Lost time +++ if life-threatening bleedings : intracranial and others Lost time +++ if major bleedings in EDs

Conclusion (3/3) Need of teaching program : fight against non scientific historic fears. Need of multicentric trials in France and Europen. Evaluate the acccuracy and the safety of PCC. Show PCC as an antidote As malignancy hyperthermia in anaesthesia care, organize the management of bleeding under VKA with standardized written procedure.

As soon as diagnosis confirmed

As soon as possible